The addition of navtemadlin to ruxolitinib for JAK inhibitor-naive patients with myelofibrosis with suboptimal response to ...

On this episode of Onc Nurse On Call, Kristin Daly, MSN, ANP-BC, AOCNP, discusses practical cancer care strategies in the age ...

Panelists discuss how the IMscin001 trial findings established subcutaneous atezolizumab noninferiority with comparable efficacy and safety to intravenous (IV) formulation while highlighting ...

The FDA has granted approval to adjuvant cemiplimab treatment for patients with high-risk cutaneous squamous cell carcinoma ...

Jackson, the administrative director of advanced practice at the Vanderbilt-Ingram Cancer Centers in Franklin and Nashville, ...

A network to connect patients with unused medications with patients in need brought $18 million of free cancer medication ...

The use of ctDNA after surgery can provide guidance to patients who may be receiving input on treatment decisions from every ...

Panelists discuss how the subcutaneous nivolumab data demonstrate reassuring safety with minimal grade 3/4 events, how ...

AI-driven decision support can ease oncologists’ workloads and streamline care without reducing autonomy.

Following imlunestrant’s approval, Komal Jhaveri, MD, FACP, compares the oral SERD to its counterpart, elacestrant, in terms of composition and trials.

Heather J. Jackson, PhD, APRN, FNP-BC, NEA-BC, FAA-NP, shared a review of supportive oncology practices at the 2025 School of Nursing Oncology.